A Genome-wide Association Study Provides Evidence of Sex-specific Involvement of Chr1p35.1 (ZSCAN20-TLR12P) and Chr8p23.1 (HMGB1P46) With Diabetic Neuropathic Pain

EBioMedicine

Volumn 2, Issue 10, 2015, Pages 1386-1393

  Meng, Weihua ^a   Deshmukh, Harshal A ^a   Donnelly, Louise A ^a   Torrance, Nicola ^a   Colhoun, Helen M ^a   Palmer, Colin N A ^a   Smith, Blair H ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

GWAS; Heritability; Neuropathic pain; Sex specific

Indexed keywords

AGED; ARTICLE; CASE CONTROL STUDY; DIABETES MELLITUS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; CHROMOSOME 1; CHROMOSOME 8; DIABETIC NEUROPATHIES; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MIDDLE AGED; NEURALGIA; ODDS RATIO; QUANTITATIVE TRAIT LOCUS; SEX DIFFERENCE; VERY ELDERLY;

HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 PROTEIN, HUMAN;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 8; DIABETIC NEUROPATHIES; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; NEURALGIA; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; SEX FACTORS;

EID: 84949727699     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.08.001     Document Type: Article

References (65)

1. Abbott C.A., Malik R.A., van Ross E.R., Kulkarni J., Boulton A.J. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the UK. Diabetes Care 2011, 34:2220-2224.
2. Attal N., Cruccu G., Baron R., Haanpää M., Hansson P., Jensen T.S., Nurmikko T., European Federation of Neurological Societies EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010, 17:1113-e88.
3. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
4. Barrett A.M., Lucero M.A., Le T., Robinson R.L., Dworkin R.H., Chappell A.S. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med. 2007, 8(supple2):50-62.
5. Berghöfer B., Frommer T., Haley G., Fink L., Bein G., Hackstein H. TLR7 ligands induce higher IFN-alpha production in females. J. Immunol. 2006, 177:2088-2096.
6. Bettoni I., Comelli F., Rossini C., Granucci F., Giagnoni G., Peri F., Costa B. Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice. Glia 2008, 56:1312-1319.
7. Callaghan B.C., Little A.A., Feldman E.L., Hughes R.A. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst. Rev. 2012, 6:CD007543.
8. Chessell I.P., Hatcher J.P., Bountra C., Michel A.D., Hughes J.P., Green P., Egerton J., Murfin M., Richardson J., Peck W.L., Grahames C.B., Casula M.A., Yiangou Y., Birch R., Anand P., Buell G.N. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 2005, 114:386-396.
9. Chiefari E., Iiritano S., Paonessa F., Le Pera I., Arcidiacono B., Filocamo M., Foti D., Liebhaber S.A., Brunetti A. Pseudogene-mediated posttranscriptional silencing of HMGA1 can result in insulin resistance and type 2 diabetes. Nat. Commun. 2010, 1:40.
10. Cook-Sather S.D., Li J., Goebel T.K., Sussman E.M., Rehman M.A., Hakonarson H. TAOK3, a novel genome-wide association study locus associated with morphine requirement and postoperative pain in a retrospective pediatric day surgery population. Pain 2014, 155:1383-1773.
11. Davies M., Brophy S., Williams R., Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006, 29:1518-1522.
12. Dayem Ullah A.Z., Lemoine N.R., Chelala C. A practical guide for the functional annotation of genetic variations using SNPnexus. Brief. Bioinform. 2013, 14:437-447.
13. Delaneau O., Marchini J., Zagury J.F. A linear complexity phasing method for thousands of genomes. Nat. Methods 2011, 9:179-181.
14. Devor M., del Canho S., Raber P. Heritability of symptoms in the neuroma model of neuropathic pain: replication and complementation analysis. Pain 2005, 116:294-301.
15. Dieleman J.P., Kerklaan J., Huygen F.J., Bouma P.A., Sturkenboom M.C. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 2008, 137:681-688.
16. Do D.N., Ostersen T., Strathe A.B., Mark T., Jensen J., Kadarmideen H.N. Genome-wide association and systems genetic analyses of residual feed intake, daily feed consumption, backfat and weight gain in pigs. BMC Genet. 2014, 15:27.
17. Docampo E., Escaramís G., Gratacos M., Villatoro S., Puig A., Kogevinas M., Collado A., Carbonell J., Rivera J., Vidal J., Alegre J., Estivill X., Rabionet R. Genome-wide analysis of single nucleotide polymorphisms and copy number variants in fibromyalgia suggest a role for the central nervous system. Pain 2014, 155:1102-1109.
18. Dworkin R.H., Malone D.C., Panarites C.J., Armstrong E.P., Pham S.V. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J. Pain 2010, 11:360-368.
19. Fagerholm E., Ahlqvist E., Forsblom C., Sandholm N., Syreeni A., Parkkonen M., McKnight A.J., Tarnow L., Maxwell A.P., Parving H.H., Groop L., Groop P.H., FinnDiane Study Group SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes. Diabetologia 2012, 55:2386-2393.
20. Feldman P., Due M.R., Ripsch M.S., Khanna R., White F.A. The persistent release of HMGB1 contributes to tactile hyperalgesia in a rodent model of neuropathic pain. J. Neuroinflammation 2012, 9:180.
21. Fillingim R.B., Kaplan L., Staud R., Ness T.J., Glover T.L., Campbell C.M., Mogil J.S., Wallace M.R. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J. Pain 2005, 6:159-167.
22. Finnerup N.B., Sindrup S.H., Jensen T.S. The evidence for pharmacological treatment of neuropathic pain. Pain 2010, 150:573-581.
23. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, Wellcome Trust Case Control Consortium 2, Zhou K., Bellenguez C., Spencer C.C., Bennett A.J., Coleman R.L., Tavendale R., Hawley S.A., Donnelly L.A., Schofield C., Groves C.J., Burch L., Carr F., Strange A., Freeman C., Blackwell J.M., Bramon E., Brown M.A., Casas J.P., Corvin A., Craddock N., Deloukas P., Dronov S., Duncanson A., Edkins S., Gray E., Hunt S., Jankowski J., Langford C., Markus H.S., Mathew C.G., Plomin R., Rautanen A., Sawcer S.J., Samani N.J., Trembath R., Viswanathan A.C., Wood N.W., MAGIC investigators, Harries L.W., Hattersley A.T., Doney A.S., Colhoun H., Morris A.D., Sutherland C., Hardie D.G., Peltonen L., McCarthy M.I., Holman R.R., Palmer C.N., Donnelly P., Pearson E.R. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat. Genet. 2011, 43:117-120.
24. Haanpää M., Attal N., Backonja M., Baron R., Bennett M., Bouhassira D., Cruccu G., Hansson P., Haythornthwaite J.A., Iannetti G.D., Jensen T.S., Kauppila T., Nurmikko T.J., Rice A.S., Rowbotham M., Serra J., Sommer C., Smith B.H., Treede R.D. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011, 152:14-27.
25. Hall G.C., Carroll D., McQuay H.J. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Fam. Pract. 2008, 9:26.
26. Hall G.C., Morant S.V., Carroll D., Gabriel Z.L., McQuay H.J. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Fam. Pract. 2013, 14:28.
27. Howie B.N., Donnelly P., Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009, 5:e1000529.
28. Jensen T.S., Backonja M.M., Hernández Jiménez S., Tesfaye S., Valensi P., Ziegler D. New perspectives on the management of diabetic peripheral neuropathic pain. Diab. Vasc. Dis. Res. 2006, 3:108-119.
29. Jensen T.S., Baron R., Haanpaa M., Kalso E., Loeser J.D., Rice A.S., Treede R.D. A new definition of neuropathic pain. Pain 2011, 152:2204-2205.
30. Jones R.C., Backonja M.M. Review of neuropathic pain screening and assessment tools. Curr. Pain Headache Rep. 2013, 17:363.
31. Kessler T., Erdmann J., Schunkert H. Genetics of coronary artery disease and myocardial infarction-2013. Curr. Cardiol. Rep. 2013, 15:368.
32. Kim D., Kim M.A., Cho I.H., Kim M.S., Lee S., Jo E.K., Choi S.Y., Park K., Kim J.S., Akira S., Na H.S., Oh S.B., Lee S.J. A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity. J. Biol. Chem. 2007, 282:14975-14983.
33. Koblansky A.A., Jankovic D., Oh H., Hieny S., Sungnak W., Mathur R., Hayden M.S., Akira S., Sher A., Ghosh S. Recognition of profilin by toll-like receptor 12 is critical for host resistance to toxoplasma gondii. Immunity 2012, 38:119-130.
34. Krishna S.S., Majumdar I., Grishin N.V. Structural classification of zinc fingers: survey and summary. Nucleic Acids Res. 2003, 31:532-550.
35. Lee S.H., Wray N.R., Goddard M.E., Visscher P.M. Estimating missing heritability for disease from genome-wide association studies. Am. J. Hum. Genet. 2011, 88:294-305.
36. Liu T., Gao Y.J., Ji R.R. Emerging role of Toll-like receptors in the control of pain and itch. Neurosci. Bull. 2012, 28:131-144.
37. Marti C.L., Albers J., Herman W.H., Cleary P., Waberski B., Greene D.A., Stevens M.J., Feldman E.L., DCCT/EDIC Research Group Neuropathy among the diabetes control and complications trial cohort 8years after trial completion. Diabetes Care 2006, 29:340-344.
38. Meng W., Deshmukh H.A., van Zuydam N.R., Liu Y., Donnelly L.A., Zhou K., Wellcome Trust Case Control Consortium 2 (WTCCC2), Surrogate Markers for Micro- and Macro-Vascular Hard Endpoints for Innovative Diabetes Tools (SUMMIT) Study Group, Morris A.D., Colhoun H.M., Palmer C.N., Smith B.H. A genome-wide association study suggests an association of Chr8p213 (GFRA2) with diabetic neuropathic pain. Eur J Pain 2015, 19:392-399.
39. Mogil J.S., Wilson S.G., Chesler E.J., Rankin A.L., Nemmani K.V., Lariviere W.R., Groce M.K., Wallace M.R., Kaplan L., Staud R., Ness T.J., Glover T.L., Stankova M., Mayorov A., Hruby V.J., Grisel J.E., Fillingim R.B. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4867-4872.
40. Nakamura Y., Morioka N., Abe H., Zhang F.F., Hisaoka-Nakashima K., Liu K., Nishibori M., Nakata Y. Neuropathic pain in rats with a partial sciatic nerve ligation is alleviated by intravenous injection of monoclonal antibody to high mobility group box-1. PLoS One 2013, 8:e73640.
41. National Institute for Health and Care Excellence NICE (UK) Clinical Guideline 173 Neuropathic Pain - Pharmacological Management: The Pharmacological Management of Neuropathic Pain in Adults in Non-specialist Settings (http://guidanceniceorguk/CG173 (accessed 30th July 2015)).
42. Nishizawa D., Fukuda K., Kasai S., Hasegawa J., Aoki Y., Nishi A., Saita N., Koukita Y., Nagashima M., Katoh R., Satoh Y., Tagami M., Higuchi S., Ujike H., Ozaki N., Inada T., Iwata N., Sora I., Iyo M., Kondo N., Won M.J., Naruse N., Uehara-Aoyama K., Itokawa M., Koga M., Arinami T., Kaneko Y., Hayashida M., Ikeda K. Genome-wide association study identifies a potent locus associated with human opioid sensitivity. Mol. Psychiatry 2014, 19:55-62.
43. Nissenbaum J., Devor M., Seltzer Z., Gebauer M., Michaelis M., Tal M., Dorfman R., Abitbul-Yarkoni M., Lu Y., Elahipanah T., delCanho S., Minert A., Fried K., Persson A.K., Shpigler H., Shabo E., Yakir B., Pisanté A., Darvasi A. Susceptibility to chronic pain following nerve injury is genetically affected by CACNG2. Genome Res. 2010, 20:1180-1190.
44. Peters M.J., Broer L., Willemen H.L., Eiriksdottir G., Hocking L.J., Holliday K.L., Horan M.A., Meulenbelt I., Neogi T., Popham M., Schmidt C.O., Soni A., Valdes A.M., Amin N., Dennison E.M., Eijkelkamp N., Harris T.B., Hart D.J., Hofman A., Huygen F.J., Jameson K.A., Jones G.T., Launer L.J., Kerkhof H.J., de Kruijf M., McBeth J., Kloppenburg M., Ollier W.E., Oostra B., Payton A., Rivadeneira F., Smith B.H., Smith A.V., Stolk L., Teumer A., Thomson W., Uitterlinden A.G., Wang K., van Wingerden S.H., Arden N.K., Cooper C., Felson D., Gudnason V., Macfarlane G.J., Pendleton N., Slagboom P.E., Spector T.D., Völzke H., Kavelaars A., van Duijn C.M., Williams F.M., van Meurs J.B. Genome-wide association study meta-analysis of chronic widespread pain: evidence for involvement of the 5p15.2 region. Ann. Rheum. Dis. 2013, 72:427-436.
45. Pruim R.J., Welch R.P., Sanna S., Teslovich T.M., Chines P.S., Gliedt T.P., Boehnke M., Abecasis G.R., Willer C.J. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010, 26:2336-2337.
46. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
47. Roberts B.J., Dragon J.A., Moussawi M., Huber S.A. Sex-specific signaling through Toll-like receptors 2 and 4 contributes to survival outcome of Coxsackievirus B3 infection in C57Bl/6 mice. Biol. Sex Differ. 2012, 3:25.
48. Sato H., Droney J., Ross J., Olesen A.E., Staahl C., Andresen T., Branford R., Riley J., Arendt-Nielsen L., Drewes A.M. Gender, variation in opioid receptor genes and sensitivity to experimental pain. Mol. Pain 2013, 9:20.
49. Shibasaki M., Sasaki M., Miura M., Mizukoshi K., Ueno H., Hashimoto S., Tanaka Y., Amaya F. Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury. Pain 2010, 149:514-521.
50. Skol A.D., Scott L.J., Abecasis G.R., Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat. Genet. 2006, 38:209-213.
51. Smith B.H., Macfarlane G.J., Torrance N. Epidemiology of chronic pain, from the laboratory to the bus stop: time to add understanding of biological mechanisms to the study of risk factors in population-based research?. Pain 2007, 127:5-10.
52. Tan S., McNamara A., Jouvenot Y., Krisky D., Wolfe D., Compos B., Zhong X., Glorioso J., Zhang H.S., Gregory P.D. Zinc finger protein transcription factors as potential therapeutic agents for the treatment of neuropathic pain [abstract]. Mol. Ther. 2005, 11:s250.
53. Tanga F.Y., Nutile-McMenemy N., DeLeo J.A. The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5856-5861.
54. Tarride J.E., Collet J.P., Choiniere M., Rousseau C., Gordon A. The economic burden of neuropathic pain in Canada. J. Med. Econ. 2006, 9:55-68.
55. Tesfaye S., Chaturvedi N., Eaton S.E., Ward J.D., Manes C., Ionescu-Tirgoviste C., Witte D.R., Fuller J.H., EURODIAB Prospective Complications Study Group Vascular risk factors and diabetic neuropathy. N Engl J Med 2005, 352:341-350.
56. Torrance N., Smith B.H., Bennett M.I., Lee A.J. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J. Pain 2006, 7:281-289.
57. Torrance N., Smith B.H., Watson M.C., Bennett M.I. Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin. Fam. Pract. 2007, 24:481-485.
58. Torrance N., Ferguson J.A., Afolabi E., Bennett M.I., Serpell M.G., Dunn K.M., Smith B.H. Neuropathic pain in the community: more under-treated than refractory?. Pain 2013, 154:690-699.
59. Trang T., Beggs S., Wan X., Salter M.W. P2X4-receptor-mediated synthesis and release of brain-derived neurotrophic factor in microglia is dependent on calcium and p38-mitogen-activated protein kinase activation. J. Neurosci. 2009, 29:3518-3528.
60. van Hecke O., Austin S.K., Khan R.A., Smith B.H., Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 2014, 155:654-662.
61. Velegraki M., Koutala H., Tsatsanis C., Papadaki H.A. Increased levels of the high mobility group box 1 protein sustain the inflammatory bone marrow microenvironment in patients with chronic idiopathic neutropenia via activation of toll-like receptor 4. J. Clin. Immunol. 2012, 32:312-322.
62. Wang S., Dvorkin D., Da Y. SNPEVG: a graphical tool for GWAS graphing with mouse clicks. BMC Bioinf. 2012, 13:319.
63. Wang X., Grace P.M., Pham M.N., Cheng K., Strand K.A., Smith C., Li J., Watkins L.R., Yin H. Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain. FASEB J. 2013, 27:2713-2722.
64. Weiss L.A., Abney M., Cook E.H., Ober C. Sex-specific genetic architecture of whole blood serotonin levels. Am. J. Hum. Genet. 2005, 76:33-41.
65. Yu M., Wang H., Ding A., Golenbock D.T., Latz E., Czura C.J., Fenton M.J., Tracey K.J., Yang H. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26:174-179.